Tags

Type your tag names separated by a space and hit enter

Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort.
Rhinology. 2019 Aug 01; 57(4):279-286.R

Abstract

BACKGROUND

The European Union has prioritised allergic rhinitis (AR) control. A visual analogue scale (VAS) has been endorsed as the AR control language and embedded into the most recent MACVIA-ARIA guideline. This study assessed the effectiveness and safety of MP-AzeFlu using a VAS in a real-life study in Sweden.

METHODS

431 patients aged 12 years or over with ARIA-defined moderate to severe AR were included in this multicentre, prospective, non-interventional study and prescribed MP-AzeFlu. Patients assessed symptom severity using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) on Days 0, 1, 3 and 7, and after approximately 14 days in the morning before using MP-AzeFlu. Patients' perceived level of disease control was assessed on Day 3. The proportion of patients who achieved a defined VAS score cutoff for well- and partly controlled AR was also calculated.

RESULTS

MP-AzeFlu reduced mean (SD) VAS score from 67.9 (16.1) mm at baseline to 32.1 (22.8) mm on the last day. Results were consistent irrespective of severity, phenotype, patient age class or previous treatment. By Day 3, 84.0% of patients reported well- or partly controlled symptoms. Overall, 17.7%, 32.2%, 53.8% and 64.2% of patients achieved a 38 mm or greater "well-controlled" VAS score cutoff on Day 1, 3 and 7 and last day, respectively.

CONCLUSIONS

MP-AzeFlu provided rapid, effective and sustained symptom control in patients with AR from Sweden in a realworld setting, aligning with EU and MACVIA-ARIA initiatives and supporting the effectiveness of MP-AzeFlu for AR treatment in real life.

Authors+Show Affiliations

Department of Clinical Sciences, Intervention and Technology, Division of Otorhinolaryngology, Karolinska Instituet, Stockholm, Sweden.Astma och Allergimottagningen, Stockholm, Sweden.Astma och Allergimottagningen, Goteborg, Sweden.Department of Clinical Sciences, Intervention and Technology, Division of Otorhinolaryngology, Karolinska Instituet, Stockholm, Sweden.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30938376

Citation

Stjarne, P, et al. "Control of Allergic Rhinitis With MP-AzeFlu: a Noninterventional Study of a Swedish Cohort." Rhinology, vol. 57, no. 4, 2019, pp. 279-286.
Stjarne P, Strand V, Theman K, et al. Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort. Rhinology. 2019;57(4):279-286.
Stjarne, P., Strand, V., Theman, K., & Ehnhage, A. (2019). Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort. Rhinology, 57(4), 279-286. https://doi.org/10.4193/Rhin18.028
Stjarne P, et al. Control of Allergic Rhinitis With MP-AzeFlu: a Noninterventional Study of a Swedish Cohort. Rhinology. 2019 Aug 1;57(4):279-286. PubMed PMID: 30938376.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort. AU - Stjarne,P, AU - Strand,V, AU - Theman,K, AU - Ehnhage,A, PY - 2019/4/3/pubmed PY - 2019/10/8/medline PY - 2019/4/3/entrez SP - 279 EP - 286 JF - Rhinology JO - Rhinology VL - 57 IS - 4 N2 - BACKGROUND: The European Union has prioritised allergic rhinitis (AR) control. A visual analogue scale (VAS) has been endorsed as the AR control language and embedded into the most recent MACVIA-ARIA guideline. This study assessed the effectiveness and safety of MP-AzeFlu using a VAS in a real-life study in Sweden. METHODS: 431 patients aged 12 years or over with ARIA-defined moderate to severe AR were included in this multicentre, prospective, non-interventional study and prescribed MP-AzeFlu. Patients assessed symptom severity using a VAS from 0 (not at all bothersome) to 100 mm (very bothersome) on Days 0, 1, 3 and 7, and after approximately 14 days in the morning before using MP-AzeFlu. Patients' perceived level of disease control was assessed on Day 3. The proportion of patients who achieved a defined VAS score cutoff for well- and partly controlled AR was also calculated. RESULTS: MP-AzeFlu reduced mean (SD) VAS score from 67.9 (16.1) mm at baseline to 32.1 (22.8) mm on the last day. Results were consistent irrespective of severity, phenotype, patient age class or previous treatment. By Day 3, 84.0% of patients reported well- or partly controlled symptoms. Overall, 17.7%, 32.2%, 53.8% and 64.2% of patients achieved a 38 mm or greater "well-controlled" VAS score cutoff on Day 1, 3 and 7 and last day, respectively. CONCLUSIONS: MP-AzeFlu provided rapid, effective and sustained symptom control in patients with AR from Sweden in a realworld setting, aligning with EU and MACVIA-ARIA initiatives and supporting the effectiveness of MP-AzeFlu for AR treatment in real life. SN - 0300-0729 UR - https://www.unboundmedicine.com/medline/citation/30938376/Control_of_allergic_rhinitis_with_MP_AzeFlu:_a_noninterventional_study_of_a_Swedish_cohort_ L2 - https://www.rhinologyjournal.com/Abstract.php?id=1885 DB - PRIME DP - Unbound Medicine ER -